Drug Trial Radar · NCT06993233
A Study With CIT-013 in HS Patients
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
108
Actual
Start
Oct 31, 2025
Primary completion
Apr 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Citryll BVIndustry
- Sponsor type
- Industry
- First posted
- May 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if CIT-013 works to treat Hidradenitis Suppurativa in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are: Does CIT-013 lower the disease activity of HS patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of HS. Participants will: Take receive 50 or 100 mg CIT-013 or placebo every other week for 12 weeks Visit the clinic once every 2 weeks for checkups and tests Keep monitor their symptoms during this period
Conditions
- Hidradenitis Suppurativa (HS)
Interventions
CIT-013 high doseDrug
subcutaneous injection
CIT-013 medium doseDrug
subcutaneous injection
PlaceboDrug
subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with HiSCR75 on CIT 013 versus placeboTime frame: week 12
Locations
28 sites in 6 countries. Site status is shown where the registry gives one.
CA-01
Barrie, Canada
CA-05
Calgary, Canada
CA-02
London, Canada
CA-04
Newmarket, Canada
CA-03
Winnipeg, Canada
DE-06
Bad Bentheim, Germany
DE-01
Bochum, Germany
DE-04
Dresden, Germany
DE-02
Frankfurt, Germany
DE-08
Kiel, Germany
DE-03
Oldenburg, Germany
Erasmus UMC
Rotterdam, Netherlands
PL-06
Bialystok, Poland
PL-08
Gdansk, Poland
PL-03
Katowice, Poland
PL-02
Lodz, Poland
PL-10
Lodz, Poland
PL-09
Poznan, Poland
PL-01
Rzeszów, Poland
PL-05
Wroclaw, Poland
ES-05
Barcelona, Spain
ES-04
Madrid, Spain
ES-02
Santiago de Compostela, Spain
ES-03
Seville, Spain
ES-01
Valencia, Spain
GB-02
Cardiff, United Kingdom
GB-05
Chester, United Kingdom
GB-04
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.